U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

SRX19862052: GSM7142357: 4xko_IgG_2_S11; Homo sapiens; OTHER
1 ILLUMINA (Illumina HiSeq 2500) run: 31.8M spots, 1.6G bases, 729.5Mb downloads

External Id: GSM7142357_r1
Submitted by: Haffner Lab, Division of Human Biology, Fred Hutchinson Cancer Research Center
Study: Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor Through cMYC Repression and Recruitment of the DREAM Complex [CUT&RUN]
show Abstracthide Abstract
The androgen receptor (AR) pathway regulates key cell survival programs in prostate epithelium. Targeting the AR has a remarkable therapeutic index and represents a near-universal driver and therapeutic vulnerability in metastatic prostate cancer. Though most approaches directed toward the AR focus on inhibiting AR signaling, laboratory and now clinical data have shown that high dose, supraphysiological androgen treatment (SPA), results in growth repression and improved out-comes in subsets of prostate cancer patients. However, the mechanism(s) contributing to SPA re-sponse and resistance remain unclear. To characterize SPA signaling, we integrated metrics of gene expression changes induced by SPA together with cistrome data and protein-interactomes. These analyses determined that the Dimerization partner, RB-like, E2F and Multi-vulval class B (DREAM) complex mediates growth repression and downregulation of E2F targets in response to SPA. Notably, prostate cancers with complete genomic loss of RB1 responded to SPA treatment whereas loss of DREAM complex components such as RBL1/2 promoted resistance. Overexpres-sion of MYC resulted in complete resistance to SPA and attenuated the SPA/AR-mediated repres-sion of E2F target genes. These findings support a model of SPA-mediated growth repression that relies on the negative regulation of MYC by AR leading to repression of E2F1 signaling via the DREAM-SIN3A-HDAC complex. As RB1 and DREAM complex stability are regulated by MYC, a key determinant of tumor sensitivity to SPA, treatment may hinge on effectively repress-ing MYC activity. The integrity of MYC signaling and DREAM complex assembly may conse-quently serve as determinants of SPA responses and as pathways mediating SPA resistance. Overall design: This data series contains LNCaP cells and isogenic TP53/RB1 knockout cells that also have RBL1, RBL2, or both knocked out. These are also isogenic clones. IgG serve as input controls for MACS2. 4xKO samples lack RB1/RBL1/RBL2 and can serve as antibody-specific background controls for .tdf or Bigwig files. Each condition is in represented by biological triplicates (1-3)
Sample: 4xko_IgG_2_S11
SAMN34065930 • SRS17219461 • All experiments • All runs
Organism: Homo sapiens
Library:
Name: GSM7142357
Instrument: Illumina HiSeq 2500
Strategy: OTHER
Source: GENOMIC
Selection: other
Layout: PAIRED
Construction protocol: low-salt CUT&RUN protocol MicroPlex Library Preparation Kit v2 (Diagenode, catalog C05010014)
Runs: 1 run, 31.8M spots, 1.6G bases, 729.5Mb
Run# of Spots# of BasesSizePublished
SRR2406070531,812,1991.6G729.5Mb2023-05-26

ID:
27232370

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...